Previous 10 | Next 10 |
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal presentation at the 3...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development...
Enanta Pharmaceuticals, Inc. (ENTA) Q4 2020 Earnings Conference Call November 23, 2020 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration and CFO Conferen...
Image source: The Motley Fool. Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Q4 2020 Earnings Call Nov 23, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Enanta Pharmaceuticals Inc (ENTA) Q4 2020 Earnings Call Transcri...
Enanta Pharma (ENTA): Q4 GAAP EPS of -$1.46 misses by $0.52.Revenue of $23.6M (-54.0% Y/Y) misses by $2.16M.2021 Guidance: R&D Expense $145M-165M; G&A Expense $27M-33MPress Release For further details see: Enanta Pharma EPS misses by $0.52, misses on revenue
Webcast and Conference Call Today at 4:30 p.m. ET On track to initiate a Phase 2b study in adult transplant patients with respiratory syncytial virus by year-end and a Phase 2 study in pediatric patients with respiratory syncytial virus in early 2021 Readouts from two cl...
[[A]], [[AMBA]], [[CBT]], [[ENTA]], [[NTNX]], [[URBN]]For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close
Enanta Pharma (NASDAQ:ENTA) is scheduled to announce Q4 earnings results on Monday, November 23rd, after market close.The consensus EPS Estimate is -$0.97 and the consensus Revenue Estimate is $25.76M (-49.8% Y/Y).Over the last 1 year, ENTA has beaten EPS estimates 50% of the time and ha...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
News, Short Squeeze, Breakout and More Instantly...
Enanta Pharmaceuticals Inc. Company Name:
ENTA Stock Symbol:
NASDAQ Market:
Enanta Pharmaceuticals Inc. Website:
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strate...
2024-05-10 16:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Nuwellis Inc. (NUWE) rose 60.3% to $0.2741 on volume of 66,284,094 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 21.1% to $0.05 on volume of 64,247,106 shares Clearmind Medicine Inc. (CMND) rose 37.6% to $1.61 on volume ...